NCT00496795View on ClinicalTrials.gov

Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2026

Conditions
Stage III Breast Cancer AJCC V7
Interventions
OTHER

epirubicin/docetaxel sequential

Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles

Trial Locations (1)

N-5021

Dept of Oncology, Bergen

All Listed Sponsors
collaborator

Haukeland University Hospital

OTHER

lead

University of Bergen

OTHER

NCT00496795 - Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer | Biotech Hunter | Biotech Hunter